Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
This article was originally published in RPM Report
FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?
You may also be interested in...
Idea could help sponsors of complex generics, but will it extend to other ANDAs?
New pathway could restart argument between industry and FDA over what qualifies for expedited review.
Sandoz/Momenta’s Glatopa (glatiramer) met four criteria for equivalence that ‘provide overlapping and confirmatory evidence of active ingredient sameness,’ FDA says.